Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).

Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disorders, face strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.

The 11 therapeutics stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 10.5%.

Luckily, therapeutics stocks have performed well with share prices up 17.1% on average since the latest earnings results.

United Therapeutics (NASDAQ:UTHR)

Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments.

United Therapeutics reported revenues of $799.5 million, up 6.8% year on year. This print fell short of analysts’ expectations by 1.6%. Overall, it was a softer quarter for the company with a miss of analysts’ revenue and EPS estimates.

"Our commercial and clinical teams continue to deliver record results, validating our strategic objectives," said Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics.

United Therapeutics delivered the weakest performance against analyst estimates of the whole group. Interestingly, the stock is up 15% since reporting and currently trades at $477.64.

Is now the time to buy United Therapeutics? Access our full analysis of the earnings results here, it’s free.

Best Q3: Halozyme Therapeutics (NASDAQ:HALO)

Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ:HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.

Halozyme Therapeutics reported revenues of $354.3 million, up 22.1% year on year, outperforming analysts’ expectations by 3.1%. The business had an exceptional quarter with full-year EBITDA guidance exceeding analysts’ expectations and an impressive beat of analysts’ full-year EPS guidance estimates.

Halozyme Therapeutics achieved the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 8% since reporting. It currently trades at $71.51.

Is now the time to buy Halozyme Therapeutics? Access our full analysis of the earnings results here, it’s free.

BioMarin Pharmaceutical (NASDAQ:BMRN)

Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.

BioMarin Pharmaceutical reported revenues of $776.1 million, up 4.1% year on year, in line with analysts’ expectations. It was a softer quarter as it posted a significant miss of analysts’ full-year EPS guidance estimates and a significant miss of analysts’ EPS estimates.

Interestingly, the stock is up 9.3% since the results and currently trades at $57.57.

Read our full analysis of BioMarin Pharmaceutical’s results here.

Novavax (NASDAQ:NVAX)

Pioneering a nanoparticle technology that mimics the molecular structure of disease pathogens, Novavax (NASDAQ:NVAX) develops and commercializes protein-based vaccines for infectious diseases, with a primary focus on its COVID-19 vaccine and combination respiratory vaccine candidates.

Novavax reported revenues of $70.45 million, down 16.6% year on year. This result beat analysts’ expectations by 61%. Taking a step back, it was a mixed quarter as it also logged an impressive beat of analysts’ revenue estimates but a significant miss of analysts’ EPS estimates.

Novavax achieved the biggest analyst estimates beat among its peers. The stock is up 28% since reporting and currently trades at $9.85.

Read our full, actionable report on Novavax here, it’s free.

Vertex Pharmaceuticals (NASDAQ:VRTX)

Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ:VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.

Vertex Pharmaceuticals reported revenues of $3.08 billion, up 11% year on year. This print was in line with analysts’ expectations. Aside from that, it was a mixed quarter as it also recorded a beat of analysts’ EPS estimates but full-year revenue guidance meeting analysts’ expectations.

The stock is up 11.7% since reporting and currently trades at $475.70.

Read our full, actionable report on Vertex Pharmaceuticals here, it’s free.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.